First patient treated with imlifidase in an investigator-initiated Phase 2 study in ANCA-associated vasculitis
Lund, Sweden 19 July, 2023. Hansa Biopharma (“Hansa”), a pioneer in enzyme technology for rare immunological conditions, today announced first patient treated with imlifidase in an investigator-initiated phase 2 study in anti-neutrophil cytoplasmic antibody (“ANCA”)-associated vasculitis. This is the first study evaluating imlifidase, Hansa’s first-generation IgG-cleaving enzyme, in this patient population. Søren Tulstrup, President and CEO, Hansa Biopharma said, “This is an important step forward in the development of our technology platform and pipeline of drug candidates for rare